×
App Icon
The Standard e-Paper
Read Offline Anywhere
★★★★ - on Play Store
Download Now

Arthritis drug Actemra still not a solution to Covid-19

Tocilizumab an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis. [Photo: Courtesy]


The long search for a possible cure for Covid-19 is yet to be over. EMPACTA (Evaluating Minority Patients with Actemra) trial which was ongoing in the country has revealed that Actemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with Covid-19 associated pneumonia.

EMPACTA is the first global clinical trial to show efficacy with Actemra in Covid-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patients.

Get Full Access for Ksh299/Week
Unlock the Full Story — Join Thousands of Informed Kenyans Today
  • Unlimited access to all premium content
  • Uninterrupted ad-free browsing experience
  • Mobile-optimized reading experience
  • Weekly Newsletters
  • MPesa, Airtel Money and Cards accepted
Already a subscriber? Log in